Eventide Asset Management

Portfolio Co Investors 2026 for Eventide Asset Management: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Eventide Asset Management accounts for 16 tracked companies with verified cap-table data, 16 of which disclose round sizes totalling $3.2B. The median disclosed raise is $196M, and the largest is Talaris Therapeutics at $365M, ahead of Kardium ($340M) and Metagenomi ($300M).

The names that recur most often on these co-invested cap tables are Eventide Asset Management (16 companies), Third Rock Ventures (4 companies), Surveyor Capital (3 companies), Invus (3 companies), Longitude Capital (3 companies), Leaps by Bayer (3 companies). By latest disclosed round, the market skews Series B (6), Series C (4), Other Equity (1), Growth (1).

Best funded Eventide Asset Management companies

  1. Talaris Therapeutics — $365M (latest: Other Equity)
  2. Kardium — $340M (latest: Growth)
  3. Metagenomi — $300M (latest: Series B)
  4. Flare Therapeutics — $287M (latest: Series C)
  5. Spur Therapeutics — $274M
  6. Pliant Therapeutics — $251M (latest: IPO)
  7. Arch Oncology — $241M (latest: Series C)
  8. Kestra Medical Technologies, Inc. — $196M (latest: Series C)
  9. Sudo Biosciences — $188M (latest: Series B)
  10. LEXEO Therapeutics — $185M (latest: Series B)
  11. Goldfinch Biopharma — $160M (latest: Series B)
  12. Leo Cancer Care — $150M (latest: Series D)
  13. Entasis Therapeutics — $122M (latest: Series B)
  14. Mersana Therapeutics — $85M (latest: Series C)
  15. Kojin Therapeutics — $60M (latest: Series A)

Eventide Asset Management — related firms and companies (56)

Eventide Asset Management alternatives · All research reports